Crux gets FDA nod for inferior vena cava filter
Article Thumbnail ImageJuly 19, 2012 -- Crux Biomedical has received U.S. Food and Drug Administration (FDA) clearance for its inferior vena cava filter (VCF) with bidirectional retrieval.
Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Sign in using your social networking account:
Sign in using your social networking

The Crux VCF is designed to facilitate bidirectional retrieval through either the femoral or jugular veins, according to the company. In a recently completed trial presented at the 2012 Society for Interventional Radiology (SIR) meeting, researchers found a 98% success rate for both filter deployment and retrieval in 125 patients from 22 sites in the U.S., Australia, New Zealand, and Belgium.

No embolizations, migrations, or fractures were observed at six-month follow-up, Crux said.